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PERSPECTIVE
The RASputin effect
Benjamin Boettner and Linda Van Aelst1
Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA
By 1916, Rasputin had become an important figure of
the corruption of the Romanov court and its treacher-
ous, unpatriotic behavior. For many people on the
fringes of the court, Rasputin’s corruption was taken as
the cause of all of Russia’s problems itself. There was
the belief that if one could get rid of Rasputin the revo-
lution may not happen. . . . In a sense, Rasputin’s assas-
sination in December 1916, should be seen as just one of
a number of palace coup plots.
Orlando Figes
Cambridge University
Cells committed to malignancy are subject to a complex
series of events prior to reaching their full tumorigenic
potential within a given type of cancer. These events are
often distinguished by the expression of particular physi-
ological characteristics. The development of a colorectal
tumor is probably the best investigated paradigm. Ini-
tially, an epithelial cell is driven out of its normal state
to give rise to dysplastic aberrant crypt foci. Further ge-
netic events ensue that lead to the advancement through
various adenomas, each showing a specific appearance,
until a carcinoma arises that ultimately metastasizes
(Kinzler and Vogelstein 1996). More generally, tumors
originating from different cell types have individual eti-
ologies that may follow a specific path along definable
stages. What will be of broad relevance, however, is the
acquisition of a set of features that Hanahan and Wein-
berg (2000) recently defined as “the hallmarks of can-
cer.” A successful tumor needs to perform the following
tasks: it has to (1) attain independence from growth sig-
nals, (2) become insensitive to growth inhibitory mecha-
nisms, (3) escape the apoptotic machinery that detects
imbalances in cellular behavior, (4) acquire a limitless
replicative potential, (5) model its own angiogenic sup-
port system, and (6) eventually switch to an invasive and
metastatic physiology (Hanahan and Weinberg 2000).
The ability of a tumor to corrupt the normal cellular cir-
cuitries that underlie these aspects depends on distinct
genetic alterations accumulating in a single cancer cell.
The Ras oncogenes N-RAS, H-RAS, and K-RAS are
mutated in 30% of human cancers (Bos 1989), and their
principle function has been ascribed to point (1) of the
above aspects, namely, the conveyance of growth factor
autonomy to a tumor cell. It is commonly believed that
Ras proteins in this context propagate a signal through
the Raf/MEK/MAPK cassette to the nucleus to manipu-
late the cell cycle machinery. In addition, work per-
formed in numerous laboratories over the past decade
has also revealed a potential participation of Ras in other
aspects of tumorigenicity. To give some illustrative ex-
amples, another of Ras’s activities, namely, stimulation
of the PI3-kinase/AKT pathway, is thought to exert an
anti-apoptotic effect (acquired trait 3; Downward 1998).
Furthermore, oncogenic Ras has been implicated in the
control of vascular endothelial growth factor (VEGF), and
interfering with the Ras/Raf/MAPK pathway in endothe-
lial cells disrupts neovascularization in vivo (acquired
trait 5; Rak et al. 1995; Eliceiri et al. 1998). Finally, meta-
static behavior can be stimulated greatly by oncogenic
Ras (acquired trait 6; Chambers and Tuck 1993; Webb et
al. 1998). Thus, although cancer cells in many cases may
use more dominant mechanisms to counteract apopto-
sis, provoke angiogenesis, and metastasize, Ras oncopro-
teins may provide an ancillary input. These principles
have been worked out primarily in mouse systems, and
most of them are yet to be reevaluated in human cancers,
which in the light of the findings described by Hamad et
al. (2002) in this issue will attain further relevance.
Ras effect(ors)
Experimental evidence for the oncogenic potential of Ras
has been obtained mostly by classical focus-forming as-
says performed in rodent cells, such as NIH3T3 cells,
and by injection of rodent cells that have been engi-
neered to express an oncogenic transgene into immuno-
compromised mice. Whereas the former assays assess
anchorage independence under serum-starved condi-
tions, the latter informs about the ability to form a solid
tumor in vivo. Rodent fibroblasts like NIH3T3 cells are
immortalized and can be transformed by forced expres-
sion of oncogenic Ras proteins relatively efficiently. The
generation of mutant Ras variants that harbor mutations
in their effector loop region (amino acids 32–40) has been
instrumental in the further dissection of the effector
pathways that are required for Ras’s transforming activ-
ity in rodent cells (White et al. 1995; Rodriguez-Viciana
et al. 1997). This sequence of nine amino acids is highly
conserved among oncogenic Ras proteins and interacts
with immediate binding partners that, in turn, specify
1Corresponding author.
E-MAIL vanaelst@cshl.org; FAX (516) 367-8815.
Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/
gad.1020602.
GENES & DEVELOPMENT 16:2033–2038 © 2002 by Cold Spring Harbor Laboratory Press ISSN 0890-9369/02 $5.00; www.genesdev.org 2033
 Cold Spring Harbor Laboratory Press on December 18, 2013 - Published by genesdev.cshlp.orgDownloaded from 
downstream signaling. The three best investigated can-
didate effectors are the Raf-kinases that activate the
MAPK module, the p110 catalytic subunit of PI3-kinase,
a generator of the second messenger phosphatidylinosi-
tol 3,4,5-phosphate (PIP3), and RalGEF isoforms that
function as guanine nucleotide exchange factors for the
small Ral GTPase (Fig. 1). In mutant terms, a V12 mu-
tation in Ras is combined with an additional mutation
residing in the effector loop region that dictates binding
specificity. An H-RasV12/S35 protein binds exclusively to
Raf-kinases but not to PI3-kinase or RalGEFs; H-
RasV12/G37 selects for RalGEF without binding to Raf or
PI3-kinase, and H-RasV12/C40 only shows affinity for PI3-
kinase (White et al. 1995; Khosravi-Far et al. 1996; Rod-
riguez-Viciana et al. 1997). The introduction of these
double-mutant cDNAs into NIH3T3 cells unveiled a
scenario in which the Raf/MEK/MAPK cascade acts as
the principle pathway to confer oncogenic potential to
fibroblasts. However, additional important insights were
revealed in these studies. Although a Raf-specific Ras
mutant, indeed, was transforming, and this activity
could be mimicked by activated forms of Raf, such as the
artificially membrane-tethered Raf-CAAX mutant, both
transforming potentials were weaker compared with the
original H-RasV12 mutant (Khosravi-Far et al. 1996).
These attenuated phenotypes could be reinforced signifi-
cantly by simultaneous expression of constitutively ac-
tive PI3-kinase or RalGEF variants (Urano et al. 1996;
White et al. 1996; Rodriguez-Viciana et al. 1997). In con-
trast, dominant-negative mutants of PI3-kinase or domi-
nant-negative Ral protein can diminish the focus-form-
ing activity of H-RasV12 (Urano et al. 1996; Rodriguez-
Viciana et al. 1997). Together, this and other experimental
evidence has led to a conceptual framework in which
Raf-induced signaling via MAPK transmits the key
transforming signal emanating from Ras, but the facili-
tating effects of other Ras-induced pathways are required
concurrently.
Ras takes different routes in the transformation
of mouse and human cells
When comparing the range of human cancers with mu-
tations in one of the Ras (N-RAS, H-RAS, and K-RAS)
genes with the tumor types arising in mice that have
been genetically engineered to produce constitutively ac-
tive forms of Ras, a number of discrepancies surface.
This is not a phenomenon unique to Ras, but can be
considered a recurrent theme intrinsic to a number of
such interspecies comparisons. Mice lacking functional
copies of tumor suppressor genes, such as p53, NF-1, and
Rb, are prone to develop incompletely overlapping sets
of tumors compared with human cancer patients carry-
ing analogous mutations (Donehower et al. 1992; Jacks
et al. 1992, 1994). RAS mutations in human subjects
occur at high frequency in tumors derived from colon,
pancreatic, lung, and thyroid tissues (Bos 1989). Whereas
the importance of mutational K-ras activation for the
onset of lung cancer has been elegantly shown in mice
(Johnson et al. 2001), tumors in pancreatic, colon, or thy-
roid environments have not been observed in mice car-
rying an oncogenic copy of ras. In contrast, rodents show
a preponderance of breast and skin cancers in response to
carcinogens (Zarbl et al. 1985; Quintanilla et al. 1986;
Miyamoto et al. 1990), whereas human breast cancers
very rarely result from RAS mutations.
Prompted by these inconsistencies, Hamad and her co-
workers (2002) asked whether the different patterns in
tumor formation in mice versus humans could be caused
by a difference in effector usage by Ras, and they un-
earthed some surprising results. The authors based their
experiments on an important previous finding by Hahn
and colleagues (1999). Until recently, the transformation
of human cells in a research environment has been im-
possible because, unlike mouse cells, they are subject to
replicative senescence (see acquired trait 4 above). Ex-
perimentally, introduction of oncogenic RAS into pri-
mary cells rapidly drives them into premature cellular
senescence (Serrano et al. 1997), thwarting any further
analysis. Many tumors breach the senescence barrier by
up-regulating the catalytically active component of
telomerase, hTERT (Bryan and Cech 1999), and Hahn
and coworkers (1999) were able to successfully transform
human cells by simultaneous expression of hTERT, the
early region of the simian virus 40, and oncogenic RAS.
In their present paper, Hamad and her colleagues (2002)
used the same tools to examine the H-Ras effector loop
mutants described above for their transforming effects in
Figure 1. Ras-dependent effector pathways in
mouse and human involved in tumorigenesis. (Left)
Mouse paradigm is depicted. The activation of Raf
(bolt arrow) by oncogenic Ras presents the major
tumorigenic effect, whereas PI3-kinase- and Ral-
GDS-controlled pathways facilitate transforma-
tion. In human cells (right) the activation of Ral-
GEF appears to be the principal transformation
pathway, although PI3-kinase and Raf-dependent
signaling is required. Other potential Ras targets
that so far have not been examined well enough are
contained in the box.
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human primary fibroblasts, primary human embryonic
kidney (HEK) epithelial cells, and human astrocytes. Sur-
prisingly, in a carefully controlled series of experiments,
the retrovirally introduced RalGEF-specific H-RasV12/G37
mutant gave rise to transformation, but the Raf- and PI3-
kinase-specific H-RasV12/S35 and H-RasV12/C40 mutants
were virtually ineffective (Fig. 1). Therefore, constitu-
tively activated H-Ras relays a transformation-essential
signal to RalGEF as tested in soft agar assays. In contrast,
activation of Raf or PI3-kinase was not sufficient to bring
about a transforming effect in human cells. Further ex-
perimentation convincingly corroborated these findings.
Neither an activated form of Raf, Raf1-22W, nor a con-
stitutively active PI3-kinase subunit, p110-CAAX, was
able to transform human cells, individually or coopera-
tively. On the other hand, mere expression of a consti-
tutively active RalGEF could master transformation of
HEK cells, and the introduction of a dominant-negative
RalA mutant, RalAN28, suppressed transformation by
H-RasV12/G37. Thus, activation of the RalGEF effector
branch by RAS appears to be a necessary requirement for
the transformation of human cells. However, Hamad and
her colleagues observed that activated Raf and PI3-ki-
nase mutants enhanced the H-RasV12/G37 oncogenic ef-
fect. This is even more clearly reflected in experiments
performed in immuno-compromised mice inoculated
with the Ras-manipulated human HEK cells. In this
more complex system, the H-RasV12/G37 mutant on its
own did not give rise to tumor formation, and neither did
the other effector loop variants. Concurrent expression
of all three mutants, in contrast, was highly tumori-
genic, but omission of the H-RasV12/G37mutant elimi-
nates tumorigenicity.
Taken together, these data disclose fundamental dif-
ferences in the mechanistics with which Ras may signal
in mouse and human tumor cells. Their observations led
the authors to hypothesize a model in which RalGEF
activation downstream of Ras is essential for its onco-
genic potential in human cancers, and they suggest that
the cooperation of Raf and PI3-kinase effector pathways
are required to elicit tumor growth in vivo (Fig. 1).
How could RalGEFs promote tumor formation
downstream of Ras?
Given that MAPK provides the major proliferative signal
in Ras-transformed mouse NIH3T3 cells, the prolifera-
tive activity of RalGEF in human cells necessitates an
alternative cell cycle stimulatory pathway. Indeed, Ha-
mad et al. (2002) excluded any MAPK elevating activity
of the H-RasV12/G37 mutant in human cells. To date,
there is sparse evidence for an impact of Ral GTPases on
the cell cycle machinery. Earlier, Gille and Downward
(1999) described a positive effect of an activated mutant
form of a RalGEF family member, Rlf-CAAX, on cyclin
D1 transcription and E2F activity, two principal agents
of G1/S progression in human cells (Gille and Downward
1999; Wolthuis and Bos 1999). This was corroborated by
Henry et al. (2000), who reported that activated Ral can
elevate the transcription level of cyclin D1 as well. Ral
appears to impinge on cyclin D1 transcription in an NF-
B-dependent fashion by activating the cytoplasmically
dormant factor that then, in turn, binds to an NF-B-
specific element in the cyclin D1 promotor (Henry et al.
2000). Also, MAPK activation by Ras in various systems
triggers the cyclin D1 promotor but does so in a different
way (Cheng et al. 1998). These potential mechanisms
have been determined in rodent fibroblasts, and there is
a strong need to reevaluate them in human cells affected
by Ras. It is noteworthy that Yamazaki et al. (2001) per-
formed experiments in human fibrosarcoma (HT1080)
cells that can grow anchorage-independently in soft agar
owing to an activating mutation in their N-RAS gene.
Dominant-negative Ral could interfere with this pheno-
type. Furthermore, once adhesion of HT1080 cells was
abrogated constitutively, activated Ral appeared to de-
crease the levels of p27Kip1, an inhibitor of cell cycle-
promoting cyclin/CDK complexes, whereas the opposite
effect was observed with dominant-negative Ral
(Yamazaki et al. 2001). Of interest, de Ruiter and col-
leagues (2001) showed that in the context of the human
DLD1 colon carcinoma cell line, a Ras/Ral-specific path-
way leads to the phosphorylation of the forkhead tran-
scription factor AFX at two critical residues. This modi-
fication represses the transcriptional activity of the lat-
ter to decrease the level of the p27Kip1 cell cycle
inhibitor, consequently alleviating G1 progression of the
cell cycle (de Ruiter et al. 2001). p27Kip1 degradation was
also found to be facilitated by Rho GTPase-dependent
signaling, which is also thought to be active downstream
of oncogenic Ras (Weber et al. 1997; Hu et al. 1999).
Thus, disabling p27Kip1 may be a function of several
pathways that are governed by Ras.
Apart from cell cycle-directed effects, several other
cellular activities of Ral are beginning to emerge. Ral, by
virtue of its binding partner RalBP1/RLIP76, modulates
the internalization of growth factor-dependent receptors,
such as epidermal growth factor (EGF) receptor and in-
sulin receptor (Nakashima et al. 1999; Jullien-Flores et
al. 2000). Both constitutively active and dominant-nega-
tive mutants of Ral efficiently block EGF uptake in hu-
man A431 epithelial carcinoma and other cells (Na-
kashima et al. 1999). This is suggestive of the notion that
Ral needs to cycle between its GTP- and GDP-bound
forms under normal homeostatic circumstances and that
its overactivation by oncogenic Ras could shift the bal-
ance to allow sustained activity of EGF receptors. Inter-
estingly, A431 cells that are exposed to EGF are induced
to proliferate and to show metastasis-associated proper-
ties. Interestingly, EGF-receptor engagement also has
been demonstrated to stimulate Src-kinase with an im-
pact on its own internalization (Wilde et al. 1999). More
recently, Goi et al. (2000) were able to show that EGF-
dependent Src activation depends on Ral activity, and
they expanded the spectrum of Src-substrates in this
pathway by including Stat3 and cortactin to the list.
Thus, it will be interesting to see whether an EGF/Ral/
Src pathway negatively feeds back to promote the up-
take of EGF-receptors. Interference with growth factor
receptor internalization by Ral may well be generalized
The RASputin effect
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to other cancer-relevant receptor tyrosine kinase sys-
tems in the future. Another, more recently discovered
function of Ral is its association with the exocyst, a mul-
tisubunit complex that, in polarized cells like those
of neuronal and epithelial lineages, governs the vectorial
transport of a subset of secretory vesicles. One of its
components, Sec5, has been identified as a Ral-effector
(Brymora et al. 2001; Moskalenko et al. 2002).
Moskalenko and his coworkers (2002) interfered with
Ral activity using multiple approaches, including ecto-
pic expression of dominant Ral mutants and RalA-
directed RNAi, and they conclusively showed that en-
dogenous Ral-regulation is required for proper exocyst
function. GFP-labeled EGF receptors, for example, mis-
localize when normal Ral activity is abolished
(Moskalenko et al. 2002). Hence, membrane trafficking
events both endocytic and exocytic in nature are criti-
cally regulated by Ral. At this point, there is no evidence
that these phenomena participate in the proliferative ef-
fect of oncogenic Ras in human cells, but it will be ex-
citing to follow the experiments that may further test a
possible participation of these pathways in tumor forma-
tion.
It should be kept in mind, that although an activated
RalGEF could mimic the transforming effect of
H-RasV12/G37, it did not do so as effectively as the Ras
mutant, suggesting that RasV12/G37 may engage other ef-
fectors to exert its full oncogenicity (Fig. 1). Certainly, it
will be interesting to monitor whether this mutant can
interact with other potential Ras partners such as Nore
(Khokhlatchev et al. 2002), Rin (Han and Colicelli 1995),
and AF-6 (Van Aelst et al. 1995), but the generated evi-
dence for a relevant role of a RalGEF/Ral effector path-
way promoting transformation in human cells is strik-
ing. In mouse cells the inhibition of a number of signal-
ing molecules that are believed to exert a function
downstream of Ras also curbs Ras’s transforming po-
tential. For example, particular functions of the Rho
GTPases, namely, Rho, Rac, and Cdc42, downstream of
oncogenic Ras have been found to contribute to trans-
formation. Moreover, Rho family activators can act as
oncogenes in rodent assays and have been found to be
mutated in human cancers (Boettner and Van Aelst
2002). Strikingly, gene-targeted mice lacking both func-
tional copies of the TIAM gene, which encodes a Rac
activator, are resistent to Ras-induced skin tumori-
genesis (Malliri et al. 2002). The means by which Rho
GTPases are activated by oncogenic Ras remains an open
issue, but there is mounting evidence for their contribu-
tion to cancer development in humans.
Does function follow redundancy?
The proposed principal transformation pathway emanat-
ing from Ras in human cells leads to the induction of
RalGEF, which, in turn, stimulates the exchange of Ral
GDP for GTP. However, this pathway will most cer-
tainly prove to be more complex. There are multiple
variants of oncogenic Ras as well as of RalGEF and Ral.
Differences in expression levels and timing, as well as
different subcellular localizations of these isoforms,
could further complicate the matter. Whereas most can-
cer studies, including the one by Hamad et al. (2002),
have been conducted with H-RAS, it will be interesting
to see whether K-RAS and N-RAS will yield the same
patterns in human cells. In particular, K-RAS will be of
importance, because it is the predominantly mutated
RAS gene in human cancers (Ellis and Clark 2000). From
a developmental point of view, gene-targeting studies in
mice have revealed that it is only the loss of K-Ras func-
tion that is essential for mouse embryonic development,
whereas N-Ras and H-Ras are dispensable (Johnson et al.
1997). This could be a reflection of differences in expres-
sion between different types of Ras in different tissues,
with K-Ras being the most common isoform. Alterna-
tively, K-Ras, N-Ras, and H-Ras could all be ubiqui-
tously expressed but perform slightly distinct roles, with
K-Ras taking center stage. If the latter were true, the
prevalence of mutationally activated K-Ras in cancer
could mirror this dominance. There also is mounting
evidence for a differential localization of Ras isoforms.
Whereas H-Ras has been traced to lipid rafts, cholesterol-
enriched patches within the plasma membrane, K-Ras
appears to be excluded from them and instead is targeted
to the disordered plasma membrane (Prior and Hancock
2001). Moreover, Chiu et al. (2002) presented evidence
that H-Ras and N-Ras can be activated and form produc-
tive signaling complexes in the endoplasmic reticulum
and Golgi compartments. These observations clearly
could have implications for effector availability, interac-
tions, and the initiation of downstream signals. In the
light of the findings by Hamad et al. (2002), in particular,
expression and subcellular compartmentalization of Ral-
GEF family members could be important.
As mentioned above, there are several RalGEF family
isoforms as well (Wolthuis and Bos 1999; de Bruyn et al.
2000; Rebhun et al. 2000; Shao and Andres 2000). Mem-
bers of RalGDS, Rgl, and Rlf subfamilies comprise a sub-
group of Ral activators that, owing to a C-terminal Ras-
binding domain (RBD), all can interact with oncogenic
Ras (Wolthuis and Bos 1999). Hamad et al. (2002) have
chosen Rlf for their experiments because this member of
the family had shown the most pronounced Ras-associa-
tion in previous studies (Esser et al. 1998), but others
might fulfill an equivalent function. However, given the
pleiotropy among Ras GTPases and RalGEF proteins,
there may be preferential matches occurring in vivo that
are of particular relevance for the development of certain
tumor types.
Conclusion
In summary, the analysis of effector specification in Ras-
induced tumorigenesis that Hamad and her colleagues
(2002) conducted in a strictly comparative way in mouse
and human cells suggests fundamental differences be-
tween the two systems. Whereas in mice Ras sends its
oncogenic signal primarily through Raf, in human cells
the oncogene appears to depend mainly on its RalGEF
effector branch for its transforming ability. It should be
Boettner and Van Aelst
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emphasized that, at the same time, Raf- and PI3-kinase
controlled pathways are additionally required for tumor
formation. This is illustrated by the fact that genetic loci
encoding components of both pathways have been found
to be mutationally modified in tumors (Phillips et al.
1998; Cantley and Neel 1999; Hoshino et al. 1999; Ma et
al. 2000). Most recently, a genome-wide cancer study has
led to the identification of BRAF mutations in human
tumor cell lines (Davies et al. 2002). It awaits to be seen
whether this or other endeavors will detect aberrant al-
leles or misfunction of Ral signaling elements. The bio-
chemical investigation of the molecular connections be-
tween Ral signaling and the cell cycle machinery will
become an area diligently pursued. As in the case of can-
cer trials that aim to intervene pharmacologically with
Raf/MEK/MAPK signaling components (Stevenson et al.
1999; Cunningham et al. 2000; Sebolt-Leopold 2000), el-
ements of the RalGEF/Ral pathway may well become
attractive target molecules. However, irrespective of
these questions, the present study by Hamad et al. (2002)
should cause appreciation of the fact that tumor biology
in humans on the mechanistic level may not always be
explicable by simple extrapolation from more tractable
experimental systems like the mouse.
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